Piflufolastat f 18 - pylarify
Active Awarded Last action
- Contract number
- 36C26226F0051
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,082,616
Award facts
- Contract value 100% obligated
- $1,082,616.00 Current and potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order awards $1.08M to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. The contract is funded by the Department of Veterans Affairs through Veterans Integrated Service Network 22 and will be performed at the contractor's facility in North Billerica, Massachusetts, with an ultimate completion date of October 31, 2026. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries no set-aside designation, utilizing a firm fixed-price structure for product delivery.
This award represents a child contract under a larger Indefinite Delivery Vehicle framework through which the VA and other federal healthcare agencies procure critical radiopharmaceutical imaging products. Progenics Pharmaceuticals, operating as a subsidiary of Lantheus Holdings, Inc., maintains significant federal supply agreements with potential values reaching $290M, enabling efficient ordering of PYLARIFY and related nuclear medicine supplies across VA medical centers and military treatment facilities nationwide. The radiopharmaceutical supports the VA's diagnostic imaging programs and oncology screening initiatives, particularly for prostate cancer detection among the veteran population served by VISN 22.
Quick answers
Who was awarded contract 36C26226F0051?
36C26226F0051 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on November 1, 2025.
How much is contract 36C26226F0051 worth?
The government has obligated $1,082,616 on 36C26226F0051.
Is contract 36C26226F0051 an order under another contract?
Yes. 36C26226F0051 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26226F0051 competed?
The extent of competition for 36C26226F0051 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award